The Korea Herald reported that Celltrion will begin preparations to build its first overseas production plant this year and confirm a site for the biologics facility before June, according to the South Korean company's chairman Seo Jeong-jin.
The upcoming facility will ensure stable supplies as well as leverage on economies of scale to further lower the prices of its biosimilar drugs, Seo said.
Celltrion's Remicade-referencing biosimilar, Remsima, is being sold in the US and Europe, while its Truxima and Herzuma, referencing Rituxan and Herceptin, respectively, have been launched in Europe.
Seo also highlighted the strength of Celltrion's pipeline, comparing Celltrion to the likes of global pharmaceutical companies such as Amgen and Roche's Genentech unit. He further pledged to smoothly carry out clinical trials for the company's newest biosimilars, including those referencing Humira and Avastin.
In the case of Humira, Celltrion plans to develop its biosimilar as a high-concentrate formula to set itself above competitive products. It also expects to become the first company worldwide to bring an Avastin-referencing biosimilar to the market, kicking off its sales with a "first-mover advantage," Seo said.
To read more NewsPoints articles, click here.